← Daiichi Sankyo (DSKYF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Daiichi Sankyo (DSKYF)
Healthcare · market cap $34.8B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-20 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Daiichi Sankyo (DSKYF) is a Japanese healthcare company with approximately 19,765 employees and a market cap of roughly $28.8B. The company fields an extensive pipeline spanning ADC platforms (T-DXd, DS-8201a, Patritumab Deruxtecan, R-DXd, Datopotamab Deruxtecan), oncology small molecules (Quizartinib, Valemetostat), and cardiovascular/metabolic assets, with multiple Phase 3 readouts expected in the near term. The most proximate catalyst is a Phase 3 T-DXd data event estimated for August 2026, rated high-importance.
The catalyst path
- 2026-10-20 (est.)Phase 2 · DS-3939aimp 7/10
- 2026-11-11 (est.)Phase 3 · Taxaneimp 9/10
- 2026-12-30 (est.)Phase 2 · Trastzumab Deruxtecanimp 7/10
- 2027-01-31 (est.)Phase 2 · DS-5141bimp 7/10
- 2027-04-11 (est.)Phase 2 · U3-1402imp 7/10
- 2027-04-30 (est.)Phase 2 · Ifinatamab deruxtecan (I-DXd)imp 7/10
- 2027-05-01 (est.)Phase 2 · 89Zr-Patritumab deruxtecanimp 7/10
- 2027-06-12 (est.)Phase 2 · I-DXdimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CS-7017 | Phase 2 | Advanced Non-small Cell Lung Cancer (NSCLC) |
| Dalteparin | Phase 3 | Venous Thromboembolism (VTE) |
| Patritumab Deruxtecan (Fixed dose) | Phase 2 | Non-Small Cell Lung Cancer Metastatic |
| Carperitide | Phase 2 | Heart Failure, Congestive |
| DS-5670a | Phase 2 | Covid19 |
| cevimeline hydrochloride | Phase 3 | Head and Neck Cancer |
| T-DXd | Phase 3 | Advanced Cancer |
| Quizartinib | Phase 3 | Leukemia |
| DU-176b tablets | Phase 2 | Atrial Fibrillation |
| DS-8201a | Phase 3 | Neoplasm, Gastrointestinal |
| Trastuzumab Deruxtecan | Phase 3 | Gastric Cancer |
| CS-3150 | Phase 3 | Essential Hypertension |
| Patritumab Deruxtecan | Phase 3 | Nonsquamous Non-small Cell Lung Cancer |
| soblidotin | Phase 2 | Lung Cancer |
| R-DXd | Phase 3 | Solid Cancer |
| Edoxaban-based Regimen | Phase 3 | Atrial Fibrillation |
| DS-8500a 25 mg | Phase 2 | Type 2 Diabetes Mellitus |
| Transdermal Patch | Phase 3 | Trauma |
| VN-0200 | Phase 2 | Respiratory Syncytial Virus Infections |
| DS-3939a | Phase 2 | Advanced Solid Tumor |
Price & technical context
3-month
+11.8%
6-month
-3.9%
12-month
-21.9%
52-wk range
$14.76–$28.90
vs 50-day MA
-0.3%
vs 200-day MA
-2.7%
Realized vol
68.1%
Max drawdown
-63.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DSKYF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.